Mechanisms of Action of the Novel Sulfonamide Anticancer Agent E7070 on Cell Cycle Progression in Human Non-small Cell Lung Cancer Cells

Overview

Journal Invest New Drugs

Publisher Springer

Specialty Oncology

Date 2001 Sep 20

PMID 11561678

Citations 33

Authors

K Fukuoka

J Usuda

Y Iwamoto

H Fukumoto

T Nakamura

T Yoneda

N Narita

N Saijo

K Nishio

Affiliations

Soon will be listed here.

Abstract

E7070 is a novel sulfonamide antitumor agent that exhibits potent antitumor activity in vitro and in vivo. This compound affects cell cycle progression in human tumor cells. To elucidate the mechanisms by which E7070 inhibits tumor cell growth, we established and characterized an E7070-resistant subline, A549/ER, from a human non-small cell lung cancer cell line A549. Flow cytometric analyses demonstrated an increase in G0/G1 and a decrease in S phase populations in cells treated with E7070 at 20 or 100 microg/ml for 24 h. Longer exposure to E7070, i.e. 48 and 72 h, increased the G2/M phase fraction in A549 cells. These inhibitory actions of E7070 on cell cycle progression were not observed in A549/ER cells. E7070 inhibited the phosphorylation of pRb, decreased expressions of cyclin A, B1, CDK2, and CDC2 proteins, and suppressed CDK2 catalytic activity with the induction of p53 and p21 proteins in A549 cells but not in A549/ER cells. Taken together, these results suggest that E7070 exerts its antitumor effects by disturbing the cell cycle at multiple points, including both the G1/S and the G2/M transition, in human lung cancer cells.

Citing Articles

Novel sulfonamides unveiled as potent anti-lung cancer agents tumor pyruvate kinase M2 activation.

Das R, Chatterjee D, Kapoor S, Vyas H, Shard A RSC Med Chem. 2024; 15(9):3070-3091.

PMID: 39309364 PMC: 11411637. DOI: 10.1039/d4md00367e.

Recent advances in anticancer mechanisms of molecular glue degraders: focus on RBM39-dgrading synthetic sulfonamide such as indisulam, E7820, tasisulam, and chloroquinoxaline sulfonamide.

Jang J, Kim J, Lee T Genes Genomics. 2024; 46(12):1345-1361.

PMID: 39271535 DOI: 10.1007/s13258-024-01565-z.

Indisulam synergizes with melphalan to inhibit Multiple Myeloma malignancy via targeting TOP2A.

Wu C, Wu C, Liu J, Jia M, Zeng X, Fu Z PLoS One. 2024; 19(4):e0299019.

PMID: 38593113 PMC: 11003618. DOI: 10.1371/journal.pone.0299019.

Applications of protein ubiquitylation and deubiquitylation in drug discovery.

Chen Y, Xue H, Jin J J Biol Chem. 2024; 300(5):107264.

PMID: 38582446 PMC: 11087986. DOI: 10.1016/j.jbc.2024.107264.

Inflammation as a driver of hematological malignancies.

Saluja S, Bansal I, Bhardwaj R, Beg M, Palanichamy J Front Oncol. 2024; 14:1347402.

PMID: 38571491 PMC: 10987768. DOI: 10.3389/fonc.2024.1347402.

References

Inokoshi J, Katagiri M, Arima S, Tanaka H, Hayashi M, Kim Y . Neuronal differentiation of neuro 2a cells by inhibitors of cell cycle progression, trichostatin A and butyrolactone I. Biochem Biophys Res Commun. 1999; 256(2):372-6. DOI: 10.1006/bbrc.1999.0316. View

Kitagawa M, Higashi H, Takahashi I, Okabe T, Ogino H, Taya Y . A cyclin-dependent kinase inhibitor, butyrolactone I, inhibits phosphorylation of RB protein and cell cycle progression. Oncogene. 1994; 9(9):2549-57. View

Laird A, Shalloway D . Oncoprotein signalling and mitosis. Cell Signal. 1997; 9(3-4):249-55. DOI: 10.1016/s0898-6568(96)00176-3. View

Nishio K, Fujiwara Y, Miyahara Y, Takeda Y, Ohira T, Kubota N . Cis-diamminedichloroplatinum(II) inhibits p34cdc2 protein kinase in human lung-cancer cells. Int J Cancer. 1993; 55(4):616-22. DOI: 10.1002/ijc.2910550417. View

Yoshimatsu K, Yamaguchi A, Yoshino H, Koyanagi N, Kitoh K . Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res. 1997; 57(15):3208-13. View

Yamamoto K, Noda K, Yoshimura A, Fukuoka M, Furuse K, Niitani H . Phase I study of E7010. Cancer Chemother Pharmacol. 1998; 42(2):127-34. DOI: 10.1007/s002800050795. View

Meijer L . Chemical inhibitors of cyclin-dependent kinases. Prog Cell Cycle Res. 1995; 1:351-63. DOI: 10.1007/978-1-4615-1809-9_29. View

Fukuoka K, Nishio K, Fukumoto H, Arioka H, Kurokawa H, Ishida T . Ectopic p16(ink4) expression enhances CPT-11-induced apoptosis through increased delay in S-phase progression in human non-small-cell-lung-cancer cells. Int J Cancer. 2000; 86(2):197-203. DOI: 10.1002/(sici)1097-0215(20000415)86:2<197::aid-ijc8>3.0.co;2-v. View

Kanzawa F, Sugimoto Y, Minato K, Kasahara K, Bungo M, Nakagawa K . Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res. 1990; 50(18):5919-24. View

10.

Sausville E, Zaharevitz D, Gussio R, Meijer L, Kunick C, Schultz R . Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target. Pharmacol Ther. 1999; 82(2-3):285-92. DOI: 10.1016/s0163-7258(98)00062-x. View

11.

Weinberg R . The retinoblastoma protein and cell cycle control. Cell. 1995; 81(3):323-30. DOI: 10.1016/0092-8674(95)90385-2. View

12.

Terada N, Lucas J, Szepesi A, Franklin R, Domenico J, Gelfand E . Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle. J Cell Physiol. 1993; 154(1):7-15. DOI: 10.1002/jcp.1041540103. View

13.

Carlson B, Dubay M, Sausville E, Brizuela L, Worland P . Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res. 1996; 56(13):2973-8. View

14.

Shao R, Cao C, Shimizu T, OConnor P, Kohn K, Pommier Y . Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res. 1997; 57(18):4029-35. View

15.

Hunter T, Pines J . Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell. 1994; 79(4):573-82. DOI: 10.1016/0092-8674(94)90543-6. View

16.

Coleman T, Dunphy W . Cdc2 regulatory factors. Curr Opin Cell Biol. 1994; 6(6):877-82. DOI: 10.1016/0955-0674(94)90060-4. View

17.

Schnier J, Gadbois D, Nishi K, Bradbury E . The kinase inhibitor staurosporine induces G1 arrest at two points: effect on retinoblastoma protein phosphorylation and cyclin-dependent kinase 2 in normal and transformed cells. Cancer Res. 1994; 54(22):5959-63. View

18.

Alessi F, Quarta S, Savio M, Riva F, Rossi L, Stivala L . The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity. Exp Cell Res. 1998; 245(1):8-18. DOI: 10.1006/excr.1998.4216. View

19.

Sun J, Qian Y, Chen Z, Marfurt J, Hamilton A, Sebti S . The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin-dependent kinase inhibitors. A potential mechanism for GGTI-298 antitumor activity. J Biol Chem. 1999; 274(11):6930-4. DOI: 10.1074/jbc.274.11.6930. View

20.

Mosmann T . Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65(1-2):55-63. DOI: 10.1016/0022-1759(83)90303-4. View